Transnasal and standard transoral endoscopies in the screening of gastric mucosal neoplasias

Table 3 Screening performance of the two esophagogastroduodenoscopies in subjects with or without chronic atrophic gastritis (mean ± SD) n (%)

	Total subjects	CAG
		Positive	Negative
Screened by transnasal EGD
Screened subjects	1382	560	822
Age (yr)	53.4 ± 15.4	60.3 ± 11.8c	47.0 ± 14.5
Males	684 (49.4)a	316 (56.4)a	368 (44.8)a
Smokers	267 (19.3)	121 (21.6)	146 (17.8)
Subjects with gastric neoplasia/DR	23/0.0166	22/0.0286c	1/0.00122a
Location of neoplasia (U/M/L)	8/7/8	8/6/8	0/1/0
Adenoma cases/DR	3/0.0022	3/0.00536	0/0
Size of adenoma (mm)	9.7 ± 4.0	9.7 ± 4.0	0
Cancer cases/DR	20/0.0145	19/0.0315c	1/0.00122
Size of cancer (mm)	32.6 ± 19.5a	34.1 ± 18.8a	5 ± 0
Morphological cancer type (I-IIa/IIb/IIc-III/Ad)	6/1/5/8	6/1/4/8	0/0/1/0
With intestinal-type cancer	18 (90.0)	18 (94.7)	0 (0)
Depth of invasion (m/sm/pm-)	5/7/8	4/7/8	1/0/0
With early cancer	12 (60.0)	11 (57.9)a	1 (100)
Screened by transoral EGD
Screened subjects	1942	800	1142
Age (yr)	53.5 ± 15.6	62.3 ± 11.4c	47.3 ± 14.2
Males	758 (39.0)	363 (45.3)	395 (34.6)
Smokers	411 (21.2)	165 (20.6)	246 (21.6)
Subjects with gastric neoplasia/DR	32/0.0164	24/0.0300c	8/0.0070
Location of neoplasia (U/M/L)	12/8/12	8/7/9	4/1/3
Adenoma cases/DR	9/0.0046	7/0.00875c	2/0.00175
Size of adenoma (mm)	10.8 ± 7.9	11.7 ± 8.8	7.5 ± 3.5
Cancer cases/DR	23/0.0118	17/0.0213c	6/0.00525
Size of cancer (mm)	22.3 ± 12.8	19.4 ± 11.7	31.4 ± 12.1
Morphological cancer type (I-IIa/IIb/IIc-III/Ad)	6/0/12/5	6/0/9/2	0/0/3/3
With intestinal-type cancer	15 (65.2)	12 (70.6)c	2 (33.3)
Depth of invasion (m/sm/pm-)	15/3/5	13/2/2	2/1/3
With early cancer	8 (78.3)	15 (88.2)	3 (50.0)

^aP < 0.05 vs transoral;

^cP < 0.05 vs CAG-negative. CAG: Chronic atrophic gastritis; DR: Detection rate; U: Upper third of the stomach; M: Middle third of the stomach; L: Lower third of the stomach; EGD: Esophagogastroduodenoscopy.